


CLAIMS:

1) Use of haloarylpyrazole compounds of formula (I)



wherein

- 10 Ar is 2,6-dichloro-4-trifluoromethylphenyl or 2-nitro-4-trifluoromethylphenyl;
 A is $S(O)_m$, $-CH=CH-$, O or NH;
 W is N and Z is CR^5 ; or W is CR^1 and Z is N or CR^5 ;
 R^1 is hydrogen, optionally substituted alkyl, halogen or $R^{20}S(O)_q$;
 R^2 and R^3 are hydrogen, alkyl, alkenyl or alkynyl, each of which is optionally
 15 substituted, aryl, cyano, halogen, nitro, YR^{20} , $S(O)_2NR^8R^9$, CHO, NR^8R^9 or $CYNR^8R^9$;
 R^4 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, acyl or
 optionally substituted alkoxycarbonyl;
 R^5 is hydrogen, alkyl, optionally substituted amino or halogen;
 R^8 and R^9 are the same or different and are hydrogen, optionally substituted alkyl,
 20 acyl or aryl;
 R^{20} is optionally substituted alkyl;
 Y is O or S;
 m is 0, 1 or 2;
 p is 0 or 1;
 25 n is 0, 1 or 2; and
 q is 0, 1 or 2,
 and in which a) any alkyl, alkoxy and alkylthio groups is of 1 to 4 carbon atoms; b)
 any alkenyl or alkynyl groups is of 2 to 5 carbon atoms; c) any substituted alkyl,
 alkoxy, alkylthio, alkenyl or alkynyl group is substituted by one or more of the same
 30 or different groups selected from halogen, YR^{20} , dihalocyclopropyl, cyano, nitro,
 optionally substituted amino, alkoxy and aryl; d) any aryl group is phenyl, optionally
 substituted, by halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, alkylthio, haloalkylthio,
 haloalkylsulphonyl, cyano or nitro; e) any acyl group is alkanoyl of 1 to 4 carbon
 atoms, or alkylsulphonyl or haloalkylsulphonyl; and f) any optionally substituted
 35 amino groups is of formula NR^8R^9 , with the proviso that when W is CR^1 and Z is CR^5
 and n and p are both 0, R^4 is not alkyl, for the manufacturing of a medicament for the
 treatment of tick infestation of animals by deterring ticks.

- 2) Use according to claim 1 characterised in that the compound is 5-chloro-1-(2, 6-dichloro-4-trifluoromethylphenyl)-4-(4,5-dicyano-1H-imidazol-2-yl-3-methyl-1-H pyrazole.
- 3) Use according to claims 1 or 2, characterised in that the compound is applied systemically to an animal.
- 4) Use according to claim 3, characterised in that the compound is applied orally to an animal.
- 5) Use according to claim 1 to 4, characterised in that the compound is applied as a tablet to an animal.
- 6) Use according to claims 1 to 5 characterised in that the compound is applied to a dog or cat.
- 7) Use according to claims 1 to 6, characterised in that the compound is applied in an initial dose of 4 mg / kg bodyweight of the animal followed by weekly administration of doses of 2 mg/kg bodyweight of the animal.
- 8) Use of 5-chloro-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(4,5-dicyano-1H-imidazol-2-yl-3-methyl-1-H pyrazole for the manufacturing of a medicament for the control of ticks for oral administration to animals in an initial dose of 4 mg / kg bodyweight of the animal followed by weekly administration of doses of 2 mg/kg bodyweight of the animal.
- 9) Use according to claim 8, characterised in that 5-chloro-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(4,5-dicyano-1H-imidazol-2-yl-3-methyl-1-H pyrazole is administered as a tablet.
- 10) Use according to claim 8 or 9, characterised in that 5-chloro-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(4,5-dicyano-1H-imidazol-2-yl-3-methyl-1-H pyrazole is administered to a dog.